Importantly, fully established MMR-deficient tumors are often sensitive to immune checkpoint inhibitors in people, which points toward MMR deficiency as an important determinant of immune checkpoint blockade (Fig. 4) efficacy, at least in certain cancer types (Le et al. 2015). The gene discussed is MRC1; the disease is cancer.